Claims for Patent: 9,993,467

Summary for Patent: 9,993,467

Title:	Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
Abstract:	Pharmaceutical compositions and single unit dosage forms of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione, or a pharmaceutically acceptable stereoisomer, prodrug, salt, solvate, hydrate, or clathrate, are provided herein. Also provided are methods of treating, managing, or preventing various disorders, such as cancer or an inflammatory disease.
Inventor(s):	Tutino; Anthony J. (New Providence, NJ), Kelly; Michael T. (Lake Hopatcong, NJ)
Assignee:	Celgene Corporation (Summit, NJ)
Application Number:	14/998,262
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,993,467
Patent Claims:	1. An oral dosage form in the form of a capsule which comprises: 1) pomalidomide at an amount of 0.1 to 3 weight percent of the total weight of the composition; 2) a binder or filler at an amount of 90 to 99 weight percent of total weight of the composition, wherein the binder or filler is a mixture of starch and mannitol; and wherein the ratio of mannitol:starch in the dosage form is from about 1:1 to about 1:1.5. 2. The oral dosage form of claim 1, wherein pomalidomide is present at an amount of 0.5 to 2 weight percent of total weight of the composition. 3. The oral dosage form of claim 1, wherein the binder or filler is present at an amount of 95 to 99 weight percent of total weight of the composition. 4. The oral dosage form of claim 1, wherein the starch is pregelatinized starch. 5. The oral dosage form of claim 1, wherein the mannitol is spray dried mannitol. 6. The oral dosage form of claim 1 further comprising a lubricant at an amount of 0.01 to 1 weight percent of total weight of the composition. 7. The oral dosage form of claim 6, wherein the lubricant is present at an amount of 0.1 to 0.5 weight percent of total weight of the composition. 8. The oral dosage form of claim 7, wherein the lubricant is sodium stearyl fumarate.